Lilly, BMS, and Incyte have each announced new AI‑focused deals to deepen artificial intelligence integration across drug discovery, development, and enterprise operations. Bristol Myers Squibb (BMS) has struck a strategic agreement with Anthropic to deploy the Claude AI model across more than 30,000 employees, embedding it into research, clinical development, manufacturing, commercial, and corporate workflows. Eli Lilly is integrating its AI engine Lilly TuneLab into Collaborative Drug Discovery’s CDD Vault, enabling biotechs to access Lilly’s proprietary data inside a secure data‑sharing environment. Incyte has expanded its partnership with Genesis Molecular AI with a $120 million upfront package ($80 million cash plus $40 million equity) and potential milestone payments that could exceed $1 billion across five initial targets. Sources: Incyte inks deal with Edison to train AI through drug discovery Eli Lilly to present at Bernstein's Strategic D... | Pluang AI Oppo...
- Get link
- X
- Other Apps